Podchaser Logo
Home
#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD

#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD

Released Monday, 3rd April 2023
Good episode? Give it some love!
#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD

#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD

#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD

#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD

Monday, 3rd April 2023
Good episode? Give it some love!
Rate Episode

Episode Transcript

Transcripts are displayed as originally observed. Some content, including advertisements may have changed.

Use Ctrl + F to search

0:00

I'm excited to announce the launch of a Curbsiders

0:02

Patreon. We love bringing you

0:04

great content like our mini series,

0:07

which we're doing new seasons of, an upgraded

0:09

website, which we just did, and more

0:11

video content, which is new in the past year.

0:14

So join our Patreon and you're going to get cash slack

0:16

admitting privileges. That helps support

0:19

the Curbsiders, plus you're going to get all

0:21

episodes of the entire show ad

0:23

free. That's old episodes and new episodes,

0:25

plus twice monthly bonus episodes with me

0:27

and Paul hanging out, recapping episodes,

0:30

doing pics of the week, answering listener questions.

0:33

It's gonna be a lot of fun. We'll also have

0:35

a Discord server exclusive to

0:37

people with cash slack admitting privileges. There's

0:39

no better way to enjoy a little

0:41

knowledge food for your brain hole. So

0:44

visit patreon.com slash

0:46

curbsiders and sign up for our Patreon.

0:48

That's patreon.com slash

0:51

curbsiders.

0:53

You

0:53

know, Paul, we're in Hershey, Pennsylvania.

0:56

And Paul, I don't know if I've talked about this before,

0:58

but I had a real problem with chocolate

1:01

and nuts and marshmallows. And

1:04

but Paul, I got over it, but

1:07

it was a rocky road. They're

1:09

going to rescind my job offer. All right.

1:13

Let's get started. The curbsiders podcast is for entertainment, education

1:16

and information purposes only. And the topics discussed should not be used

1:18

solely to diagnose, treat, cure or prevent any diseases or conditions.

1:20

Furthermore, the views and statements expressed on this podcast are solely those of those and

1:22

should not be interpreted to reflect official policy or position of any entity aside

1:24

from possibly cash like more hospital and affiliate outreach programs. If

1:27

indeed there are any, in fact, there are none. Pretty much we

1:29

are responsible if you screw up. You should always do your own homework and let us know when

1:31

we're wrong. What is

1:33

your favorite part of the show? What is

1:35

your favorite part of the show?

1:36

Welcome back to the Curbsiders. I'm Dr. Matthew Otto,

1:39

here with my great friend, Dr. Paul Nelson

1:41

Williams. Today we're gonna be talking about

1:44

HIV.

1:44

You know, what should we be, what

1:46

should we know about this as generalists

1:49

in primary care? And we have a great

1:51

guest, Dr. JJ Nunez. Paul,

1:53

before we introduce our wonderful guests, would

1:55

you tell people what is it that we do

1:56

on the curbsiders? Yeah, I often

1:59

ask myself, but thank you. Thank you, Matt. And also, by the way, thank

2:01

you, John, for that nice introduction. I have never

2:03

been introduced first in my entire life, by the way, so that was

2:05

a real thrill for me. That's nice that

2:07

I recorded for posterity. We are the

2:09

internal medicine podcast. We use expert interviews

2:12

to bring you clinical pearls and practice-changing knowledge. And

2:14

what an expert we have for you. I can say on a personal

2:17

note, I've known Dr. Nunez for

2:19

years, and he is one of those people who is, like,

2:21

annoyingly good. I don't

2:23

know if you know people like that, but, like, he's nice and then also

2:25

competent and takes good care of patients and is smart. And the type

2:28

of person who makes you feel bad about yourself if you're me at least.

2:30

So we're thrilled to have him, but I'll give a more formal bio now.

2:33

So Dr. Nunez received his medical degree from the University

2:35

of Connecticut School of Medicine, and what I want to

2:38

do is internal medicine residency at Yale New Haven Medical

2:40

Center and completed his fellowship in infectious disease

2:42

at the University of Pennsylvania with Penn Medicine.

2:44

Dr. Nunez is interested in health equity and medical

2:46

education. In addition, he has an interest

2:48

in improving access to medications for opioid use disorder,

2:53

medical and resident education, medical student and resident education,

2:55

that was probably as opposed to P, HIV primary

2:57

care and HIV-prevented medicine. So

2:59

without further ado, let's bring up Dr. Nunez. JJ. J.J.,

3:02

we're gonna tell you about Mr. Jones.

3:05

He is a 24-year-old gentleman, a self-identifying

3:07

male who presents to your

3:10

primary

3:10

care office for the establishment of care. He is transferring

3:12

care to your office after

3:14

moving to your city from out of state. Medical records are not available at

3:16

this time. So let's bring up Dr. Nunez.

3:18

JJ. All right, let's get right to a case,

3:20

right down to business. All right. JJ, we're

3:22

gonna tell you about Mr. Jones. He is a 24-year-old gentleman,

3:24

a self-identifying male, this visit. He's without

3:26

specific somatic concerns and

3:30

he reports a medical history significant for HIV

3:32

for which he takes Bictegrifir, Entercitabine,

3:35

and Tenofivir, otherwise known as Bictarvi. For

3:37

the purposes of this case, you're not an expert,

3:40

you are me, which means you are well-meaning

3:42

and you don't have a lot of experience in care of HIV, but you have

3:46

ready access to competent colleagues like yourself who are able

3:48

to do so. I feel like one

3:50

of the reasons I chose this case is this comes up in

3:52

my practice on Novacchiwado a lot where I have someone

3:54

who say their HIV is well managed by an

3:57

ID doc, but they still want somebody else for their primary care.

4:00

It's the lines get kind of blurred, and I feel like I need

4:02

a little bit of help. But for you, at a

4:04

first visit like this, where you're meeting this patient for the first time,

4:06

what are your goals, and what does this first conversation

4:08

look like for you? Yeah, so I think usually

4:11

when I'm first seeing any new patient, I

4:13

kind of always try to break the ice. I kind of introduce

4:16

myself. Mostly I try to tell them two things. I'm

4:18

slow, so I'm like molasses.

4:21

So I usually tell them probably don't

4:23

want to schedule an appointment after that, mostly

4:25

because it gives me time to really dive into a little

4:27

bit of the psychosocial stuff that's necessarily

4:30

going on. Second thing

4:32

I always tell them, I'm like Colombo. So I tend

4:34

to repeat myself a lot. And mostly I

4:36

feel like it's mostly just to pick up things that might not

4:38

have come up the first time, or maybe I

4:40

did not actually pick up when they were talking.

4:43

So I think from the first visit,

4:45

I really tried to get a sense of what brought them here

4:47

today. If they're transferring their care,

4:50

what was the reason that they're transferring care? Was

4:52

there barriers to the last practice that they're

4:54

necessarily at?

4:57

I think the other things, They're moving from a different

4:59

state. What brought them to the state?

5:01

Is it work? Is it employment?

5:04

I feel like starting off with some of those questions gives me

5:06

a little bit more about the social support as I

5:08

try to ask these questions overall.

5:12

Then during the actual visit, I think focusing

5:15

a little bit more on the HPI, mostly

5:17

of HIV, the big things I'm looking for mostly

5:20

is time of diagnosis. How

5:23

long have they been diagnosed? Are they actually

5:25

on medication? Are they taking their medication? Are they

5:27

struggling with adherence? Those are

5:29

the kind of the questions I'm necessarily asking

5:31

overall, mostly to kind of think about barriers

5:33

to care. I think we do an excellent

5:36

job of screening patients for HIV,

5:38

it's just retain patients in care, where

5:40

it's a little bit more difficult.

5:43

I noticed you mentioned Colombo. I'm 40

5:46

years old and I barely get that reference, so I'm sure

5:48

your patients really appreciate it. Yeah,

5:51

but

5:51

I wanted to ask about,

5:54

you mentioned psychosocial things is

5:56

like.

6:00

Like how, now I threw myself

6:02

off here, Paul. It's a solid joke though,

6:04

it's worth it. I just really

6:06

wanted to make the Colombo joke. No, but

6:09

at that first visit, how

6:12

much time are you getting and how much detail

6:14

are you getting into about like, you mentioned

6:16

the psychosocial stuff, so can you give an example of

6:18

like where you might spend the time on those, like

6:21

which specific issues? Sure, I think usually

6:23

I start off with just asking about the social history in the beginning,

6:26

really getting a chance to learn my patience. It makes

6:29

it easier for me to remember

6:30

who they are, especially when they're calling. So

6:32

I can really remember one or two special facts

6:34

necessarily about them. But I think the things I'm really

6:37

focusing on is in

6:39

a living situation,

6:41

things about how they interpret and

6:44

look at their disease, how do they feel

6:46

about their disease, how

6:48

do they feel about their medication management? These

6:51

are, are there things where they feel that they're empowered?

6:53

Are they feel like they're being listened to? Those

6:56

are some of the things I'm actually necessarily going through

6:58

as well. As I focus on that,

7:00

I'm also just trying to figure out if there's

7:02

issues with housing,

7:04

or if there's issues with changing

7:06

insurance, or making sure that there's coverage for the

7:08

medications. Are they having trouble

7:10

with side effects, or any reportable side effects

7:12

that I don't know about medications? So as

7:15

I go through with that, I also try to focus a little

7:17

bit more on mental health, just

7:19

to try to see where they're necessarily at. Have

7:22

they been treated before in the past for any mental

7:24

health? Are they having any barriers right now? So

7:27

a lot of times I think of it as more like a biopsychosocial

7:29

assessment than necessarily like a true

7:32

social history, actually. And then

7:34

that's where I kind of segue and make that

7:37

introduction to kind of the more

7:39

personal questions. I don't usually like to start off

7:41

with just the HIV questions, because sometimes they can

7:43

be a little bit more personable or intrusive.

7:45

So then I kind of move into the history of

7:48

like when they were diagnosed, where they've been diagnosed.

7:50

Couple questions I might focus on for that

7:52

is, have they been on medications

7:54

that worked for them, Have they been on medications that

7:57

hadn't worked for them? Are there any side effects

7:59

for me to know about?

8:00

So, you know,

8:01

what do they look for in a

8:03

provider? Those are the things I kind of focus on during

8:06

the visit. Usually I

8:08

have about 40 to 60 minutes for new patients, which

8:10

is lovely. It also

8:12

runs slow, so it's going to be a little bit longer than that. In

8:15

my practice, you know, there's days I

8:18

have social worker and case managers, so I

8:20

think we're all working together as

8:22

they work with the patients. And I think at the

8:24

end, we try to debrief and see if there's

8:27

any issues that we might have missed. is

8:29

I'm just by myself, I

8:31

feel like the first visit is really a job interview.

8:34

That's really what it is for me. I

8:36

got to make sure that this patient feels comfortable to come back.

8:39

No one really wants to go to the doctor. I don't want to go to the doctor.

8:41

The only thing I'm more popular than, maybe

8:43

the dentist, okay. But I

8:45

feel like

8:46

how much I try to focus on that visit, you

8:48

know, I might have my expectations, but

8:50

it's really measuring what expectations my patient

8:53

have. If there's an ongoing issue or

8:55

medical concern that they have, I'm gonna push

8:57

some of that aside and really just focus on that

9:00

because I think one of the big things is trying to retain

9:02

them and cares making sure that we're taking care

9:04

of the issues that they have.

9:08

This episode is brought to you by

9:11

Green Chef. And audience, you

9:13

know I love Green Chef. So does

9:15

Paul. Actually so does my family.

9:18

Green Chef is fun for me to make with

9:20

my family because let's face it, I

9:22

don't have many skills in the kitchen but Green

9:24

Chef has all the ingredients right there. It

9:27

tells me how to make it, there's pictures in the recipe,

9:30

I feel like I can get it done, and the

9:32

meals have been great. They have

9:34

over 30 recipes every week, and

9:36

they have meal plans for every lifestyle.

9:39

And you can even mix and match them if you're keto,

9:41

paleo, vegan, vegetarian, gluten free,

9:43

whatever. They got you covered.

9:46

And this month, in honor of Earth

9:48

Month, they're partnering with the One Tree Planted

9:50

Project to plant trees in Northern

9:52

Thailand. That's one tree for every

9:55

box sold. So if you're like

9:57

me, you're gonna love Green Chef. Go to

9:59

Green Chef. dot

10:00

com slash curbs 60

10:02

and use code curbs 60 to get 60% off

10:06

plus free shipping That's green

10:08

chef dot com slash curbs 60

10:11

and use the code curbs 60 to

10:13

get 60% off Plus free

10:15

shipping green chef. It's

10:17

the number one meal kit for eating

10:19

well

10:21

Other than being your usual charming excellent doctor

10:24

Lee self Is there any sort of systemic

10:26

or sort of like clinic level stuff that you can do to encourage

10:28

retention and care? And I guess, what can we

10:30

do to keep these people engaged in treatment? Because I know that there's

10:32

going to be a challenge at times. I

10:34

feel like

10:36

jumping around a lot in the sense that

10:38

I mentioned what I do. I think the first thing I

10:41

also make sure is just making sure that we're using

10:43

right pronouns. So for some of my

10:45

patients, it might be fluid. So I might

10:47

ask during each particular visit. So

10:50

I think that might be one part where

10:52

I would start. I think one of the big things that

10:54

I try to make sure during the visit is ways I can

10:56

contact my patient. There was a study that

10:58

was done at one of the Ryan Wright conferences, I wanna

11:00

say like years ago, that was one

11:02

of the biggest predictors was change in full number in

11:05

a year. So I think for me, trying to focus

11:07

out where they're at, where I can contact them,

11:09

how I can contact them, recognizing especially

11:12

for my younger adolescent or

11:15

young adult patient population, cell

11:17

phone calling them is archaic. No

11:20

one calls them, right? So it's like usually through text. So

11:22

I try to find other ways in theirs as

11:25

well. I think the other thing systemically I try

11:27

to do just see them without medical

11:29

records. If I have it, lovely, awesome. If

11:31

it's not, that's fine too. I don't find

11:33

that they're overall super helpful. You get 200 pages

11:36

of stuff that you don't necessarily need. Right?

11:39

Yeah, it's more helpful if you have a specific

11:41

question when you get that 200 page document dump

11:44

of prior records. But

11:46

I wanted to point out to the audience, because I think about

11:48

this a lot. I'm a doctor,

11:50

but I try to read and listen to

11:53

stuff that's way outside of medicine and try to apply

11:55

it to medicine. But I think if you're in the audience

11:58

and you don't see anyone who has age. I

12:00

think a lot of what you talked about is just good doctoring,

12:02

where you're just like, I start off, I want to get

12:05

details about the person so I remember who they are.

12:07

I remember their story. You're building your memory

12:10

palace of who is this person. I

12:13

think that's great. So I think people

12:15

can apply that to whatever they're doing, even

12:18

if they're not seeing any HIV in their

12:20

clinic.

12:23

And you mentioned some of the things, but

12:25

I wonder if you could just sort of role model for us

12:27

what your specific HIV history looks like. once you

12:29

have the patient comfortable with you in terms of things

12:31

like date of diagnosis

12:34

and acquisition, are there any, and

12:36

I think you touched on most of those points, but you just sort of bullet

12:38

point out what you kind of ask about when you're asking about the HIV

12:40

history specifically.

12:42

Yeah, sure. So I try to figure out where

12:44

they're necessarily coming from, when they were diagnosed,

12:47

if they've ever been hospitalized or non-hospitalized,

12:49

this gives me an idea if there's been complications. Usually

12:52

I go back to see if they've been on history of

12:54

any opportunistic infections, so can kind of

12:56

give me an idea what stage of HIV or AIDS

12:59

or complications they might have had before

13:01

in the past.

13:02

You know, medications we talk about, I really

13:04

want to make sure that we're aware of resistance,

13:07

which most patients may not necessarily know.

13:10

They just may remember, hey, this medication I was told

13:12

does not work for me overall.

13:14

I want to get a sense if they have an understanding

13:17

of what the name of their medication is. Realistically,

13:19

they're probably going to know more about their medication than

13:21

some of the providers. We just don't see

13:23

it as often. And then what pharmacy that we've been

13:26

using it, how have they been getting it, have they

13:28

had any issues for the barriers for the pharmacy?

13:30

Because sometimes if it's smaller mom and pop

13:32

shops, the medication

13:35

can sometimes be delayed for getting it compared

13:37

to some of the bigger institutions. As

13:40

for additional HIV

13:42

history, you know, other things I try to get a sense

13:45

of as well as any other co-infections, mostly

13:48

thinking about hepatitis B and hepatitis C

13:50

because it's going to determine what I do for treatment. And

13:52

then want to make sure that we really treat hep C very

13:55

early on because with co-infection, progression

13:57

to liver disease is much higher.

14:00

I also want to make sure there's social support,

14:02

actually, so just making sure, like, as we're

14:04

working about things, you know, are

14:06

there people are aware of their diagnosis, are they not

14:09

aware of their diagnosis, are they secretive about

14:11

their diagnosis, stigma. The way I ask

14:13

that's mostly like, what's been barriers for you about, you

14:15

know, taking care of your medical condition, actually.

14:19

Paul

14:19

and I were talking about this on the

14:21

drive up, up here. I mean, it, I

14:24

feel like that it's, it's a chronic disease,

14:26

we have such good treatment for it, but the

14:28

stigma and people just remember the 80s

14:31

and the 90s when everyone was dying from it and

14:33

people are still just so secretive

14:35

about it or I've still had patients tell

14:37

me, please don't test me for HIV. I'm like, what are

14:39

you worried about getting tested? And they're like, I

14:42

just don't want to, I don't even want to go there. I'm like, well, it's

14:44

a chronic disease. Like you can get treated. And so

14:47

I think there's still a lot of like misinformed

14:49

patients. You know, you brought up an excellent point, Matt,

14:52

because like

14:52

how how I

14:54

always mention is it's a chronic disease that's

14:56

easy to treat, it is in diabetes. That

14:58

may be true for me as the provider, but

15:01

it may not be the truth for the patient. I

15:03

think a couple of times I always touch base with them is

15:05

just that they can tell you the exact date that

15:07

they were diagnosed. They can tell you the exact

15:09

situation that they were in when they were diagnosed.

15:11

And for many, it was really, really traumatic, actually.

15:15

It was in a very awkward situation,

15:18

or the other thing was the involvement with the

15:20

healthcare system at that time, or

15:22

it was a complete shock. So

15:24

it's very easy for me to say, hey, it's easy to take

15:26

a pill every day. For some, it's really not.

15:29

So that's why I really try to get a sense of what

15:31

is their understanding of the disease and how do

15:33

they view themselves overall

15:35

during the visit.

15:37

And this is fairly granular. But

15:40

I wonder, how do you

15:42

document

15:44

in the record who knows about the diagnosis

15:46

and who it can be disclosed to? I feel like I don't know about

15:48

you all, but I've been involved in teams where

15:50

there's been catastrophic disclosure of diagnoses, the

15:52

family members who didn't know or that kind of thing. So is there a

15:54

way to sort of safely

15:57

sort of share that information so that you're protecting the patient the way

15:59

they need. we

16:00

were protected. Yeah, I try to keep it in

16:02

my note. I think I

16:04

try to forward with every part of my note, part

16:07

of the HIV initial history, so

16:09

that if anyone's pulling up the chart. I also try

16:11

to use stickies if we can. So

16:14

by previous medical records, you can actually put it. So

16:16

it comes up as a pop-up

16:18

that you can make sure that they're not aware of the diagnosis.

16:21

I know our medical

16:23

record here has that option too. I

16:26

just assume that no one knows, and you

16:28

shouldn't assume that anyone does. And I think

16:31

also when you're seeing patients in the hospitalized

16:33

setting, you just assume that someone in the room does not

16:35

know, actually. Because I've

16:37

had similar instances where they were accidentally

16:40

disclosed in front of people that didn't

16:42

know.

16:43

Thank you for not mentioning the medical record by

16:45

name. We bleeped that on the show. Actually,

16:47

a past guest complained to Paul and I because we

16:50

bleeped them because they said the medical record name

16:52

so many times that their colleagues

16:54

were like, why are you swearing so much on curbside?

16:57

And he's like, I wasn't swearing. I was saying the name of

16:59

a medical record. Yeah, listen, until they sponsor us. Anyway,

17:01

yeah. They're not getting free press from us. All right, Paul, should

17:03

we move on with the case? We should probably move on with the case.

17:08

All right, so Mr. Jones, in terms of getting

17:10

your excellent history, he tells you that he was diagnosed with HIV

17:12

three years ago. He states that his viral load is

17:15

undetectable. He believes his CD4 count was,

17:17

quote, pretty good at last check approximately

17:19

six months ago. He is without any other

17:21

medical issues other than occasional seasonal allergies.

17:23

He states that his parents are in good health. He reports

17:26

occasional alcohol use, smokes cannabis daily

17:28

and denies other substance use. He

17:30

is sexually active with two male partners and engages in

17:32

receptive and penetrative anal and oral sex, endorsing

17:35

routine barrier protection. He reports

17:37

a prior history of chlamydia infection about

17:39

nine months ago, and then again two years prior

17:41

to that, works as a graphic designer currently

17:44

and lives alone. We'll

17:46

get into some of the social history and some of the management

17:48

stuff, but I do want to give a space

17:50

to at least talk about your initial physical examination,

17:53

if this diagnosis changes anything that you would do, or

17:55

if it's just your routine bread and butter.

17:56

Sure. I think a lot of it's visualization actually

17:59

just like. looking at the patient if they seem anxious,

18:02

you know, overall that gives me some kind of things to kind

18:04

of look for. Also, the things I'm

18:06

looking for during my history, even though it's part

18:08

of the physical, you know, I always do

18:11

like a full review of symptoms because it might kind

18:13

of gears me if there's issues with adherence. Things

18:15

I'm looking for really is if

18:17

there's been any weight loss, any night sweats, any

18:20

fevers, you know, have they noticed any lymphadenopathy

18:24

overall because it might gear to me on what I'm going

18:26

to focus on on my necessarily exam

18:28

as well. And then thinking about the sexual history,

18:31

actually, which I'll talk about in a little bit, but

18:33

I think one of the big things is if they're having any active

18:35

symptoms, because again, you know, one of the big

18:37

things I try to do on the exam is make sure that,

18:40

you know, we're not missing anything on the diagnosis. And

18:42

then for the physical exam, you know,

18:44

really just like I tell the residents, it's

18:46

really just head to toe. But you know, a couple things for

18:48

me to kind of keep an eye on is if there's weight

18:51

loss, if the patient looks cactic.

18:54

I think other things, if there's visual field deficits,

18:56

you know, the rooms have a thaumascopes, We can use them

18:59

for reminding them that they're there, other than paper weights.

19:02

I do a good full skin exam, lymphadenopathy.

19:05

And then depending on patient preference and reading

19:07

the room, unless there's an active symptom that's

19:09

concerning for me for an STD, I also

19:12

make sure that I try to do a

19:15

sexual health exam as well. But that might

19:17

also be determined by patient comfort.

19:20

And you mentioned looking for a catexia

19:22

and everything. But one thing that I was, I guess,

19:25

not as aware of, like people

19:27

with screening for metabolic syndrome or just

19:29

like weight gain on medications, can you speak to that

19:31

a little bit? That wasn't really on my radar. Totally,

19:34

so like also part of my exam is looking

19:36

through the vitals and then also looking for like anything

19:38

that suggests of metabolic syndrome. So

19:41

why is that? Because I think, you know,

19:43

patients had mentioned that there has been weight

19:45

gain with certain HIV medications and I

19:48

think a lot of times back in my

19:50

day, as a trainee and as a

19:52

student and as a fellow, we used to always mention

19:54

that, you know, HIV is this catabolic state. You're

19:57

undetectable, you lose fat deposits.

20:00

You're on medications, that's why you're gaining

20:02

weight. Although, since

20:04

there's been newer treatment options,

20:06

which is awesome in the sense that they're

20:09

easier to take, has less reportable side

20:11

effects, they suppress the virus really well, we're

20:13

learning a lot about our patients on these new medications.

20:16

And I think there's been a lot of association with

20:18

weight gain as well. And when we

20:20

look at that, it's also not necessarily

20:23

equal actually. So I remember reading

20:25

something where about one in six patients within the next

20:27

two years will gain 10% of their body weight. actually

20:30

starting on antiretrovirals. And when you

20:32

split that even more, the weight gain's even

20:34

higher in African-Americans, and especially

20:36

African-American women, so nearly 20%

20:38

of patients. And some of these

20:40

studies, I think the one I remember is like the advanced

20:43

trial, noticed that there was a weight

20:45

gain about up to 6.4 kilos. So,

20:49

is it part of the medications? It could be. I

20:51

think some of the newer formulations, when

20:54

we used to use a lot of Tenofovir disaproxyl,

20:57

We kind of advanced to tenofovir alifinamide.

21:00

We're noticing that there is some weight gain, and there

21:02

might be even more concurrent weight gain with some of the integrase

21:04

inhibitors. So when we're thinking of dolatagravir

21:06

or bactagravir. So it's something to kind

21:09

of think of consul. So as exam wise,

21:11

it's important to note, to keep an eye on that,

21:13

because there is gonna be some weight

21:15

gain. And I think preparing patients for that, if you

21:18

wanna talk about adherence is important.

21:21

What do you do in terms of mitigation

21:23

strategies for that? I mean, I know this is not the episode

21:25

for initiation of therapy, I guess if you were at that point,

21:27

is it just an anticipatory guidance? Is there, how

21:30

do you talk to that with patients? I

21:32

think I've changed my focus on a couple

21:34

things. I think one, I really think

21:36

about talking about diet and nutrition very

21:39

early on. And then again, it's really not just that.

21:41

It's really checking if there's access

21:43

to healthy food. So I think if there's

21:45

an issue with that with patients, I might tie that in with my case

21:48

manager or local resources to kind of focus on that.

21:50

I think

21:51

three, try to really form and talk

21:53

about physical activity. When I talk

21:55

about physical activity, That's another kind of sneaky way

21:57

to kind of find out safety of the neighborhood because like there

21:59

are some neighborhoods where it's not super safe to go

22:02

exercise outside. It also has

22:04

made me rethink sometimes med switches. So

22:07

a lot of times, you know, the thought processes and your medication

22:09

comes out

22:11

super great,

22:12

less side effects, you know,

22:14

but if my patient haven't had issues to change

22:16

them, you know, sometimes it's conversations now that

22:18

I initiate, hey, there's this new option, but

22:21

let's sit down if this is the right option for you. So

22:23

I've been like rethinking some of the initiations

22:26

and switches overall. Or if

22:28

I do switch, mentioning that this

22:31

may be something that note that we will know,

22:35

actually. For the patients that

22:37

I've had some patients recently tell me that they

22:40

started doing like YouTube workouts, because you know,

22:42

like Peloton, all those things are expensive,

22:45

unattainable for a lot of patients. But like,

22:48

there's free workouts on YouTube and things. And

22:50

same thing, patients are like, my neighborhood's too dangerous.

22:52

So I don't, I don't walk around or during

22:55

the pandemic, people weren't comfortable going

22:57

outside so now they're doing that. I

23:00

did want to ask you, is it okay

23:02

to talk about labs now, Paul? Are we moving into

23:04

the initial labs or do we have something else? I can save

23:06

my question. Well, I guess while we're here in sort

23:09

of metabolic land, I guess there are any other considerations.

23:11

I know that I hear some rumblings about sort of screening

23:13

and diagnosing

23:14

diabetes and

23:16

sort of choosing labs for that and timing of the initiation

23:18

of ART and that kind of stuff. Is there anything that might

23:21

be a little bit more nuanced than we need here? But from a primary care

23:23

standpoint, is there anything that we should know about specifically between

23:25

HIV as treatments and diabetes? Yeah,

23:27

I think as part of the

23:30

one thing that's really interesting, and

23:32

I'm happy to have patients that are living longer

23:34

lives, I'm happy for the day they're cured, and I lose

23:36

my job. I tell them I'll cry tears of joy with

23:38

that. But there is a risk

23:42

for cardiovascular disease about two times

23:44

higher in patients living with HIV, even being

23:46

undetectable, and in higher

23:48

CD4 counts. So I think as we look back

23:50

at that, there's some kind of big focus

23:53

points for metabolic syndrome. You

23:55

know, I think one of the things is really being aggressive

23:57

to screen for diabetes. I

23:59

think all making sure that lipid profiles

24:01

that we're not just checking them, we're actually treating them

24:04

actually. So as we're thinking about things, you know, I have

24:06

many patients who are super well

24:08

controlled for

24:11

the HIV, their diabetes needs a

24:13

little bit of help actually. And I think

24:15

one of the big things as I focus on that is highlighting

24:17

that that's probably just as important or even

24:19

more important for mortality overall

24:22

than necessarily just treating your HIV. So

24:24

I think I tend to do a lot more

24:26

screening and then as I'm thinking about my antiretrovirals,

24:30

as we talk about switches, it's important to

24:32

think of what medication interactions there might be. I

24:35

think one of the big things is making sure that if a patient

24:37

needs to be on a statin medication to really

24:39

think about that. And you can't just go by the ACCVD

24:42

risk factor in our patients who are living with HIV

24:45

because we're not actually part of the calculation.

24:47

We know there's a risk. So as

24:50

I discuss with my patients why I'm doing

24:52

stuff. And I think one of the big things for my

24:54

patients is I feel a lot of times

24:56

overall, both non-HIV, more

24:58

meds, I'm always pushing meds, right? They want

25:00

less meds, but I try to really focus

25:02

that, hey, if you have a heart attack, there's gonna be about three

25:05

or four meds I'm gonna add onto your med list that probably won't

25:07

go off. And I think that's if

25:09

you have a minor heart attack

25:10

with no dysfunction after.

25:13

And then for, so for us, for

25:15

mostly taking off the patients for boosters for cholesterol

25:18

medications, if we can, some

25:20

of the protease inhibitors can cause dyslipidemia.

25:23

The newer ones, not as much, but compared

25:25

to the integrase inhibitors, they tend to be pretty

25:27

lipid neutral. But my dosing

25:30

for the statins can be contraindication.

25:32

I have to start with a lower dose and make sure that they're

25:34

not having any side effects. And the statins

25:37

we tend to use is Resuva statin or Torvastatin

25:39

overall. For diabetes

25:42

management, some of the longer-acting

25:44

integrase inhibitors actually do interact

25:46

with metformin. So the dosing should probably be a

25:48

little bit lower. So thinking about Della Tigrvir

25:51

and Bic Tigrvir. But

25:53

I think one of the big things is just making sure that as

25:56

a provider, we're doing just as updated

25:58

care for HIV for the... primary care. So like if

26:01

they really are indicated to get a GOP

26:03

one for diabetes really thinking about that if they

26:05

need the statin really thinking about that overall

26:08

so I tend to be pretty aggressive on that and same thing for blood

26:10

pressure control. Do you have any

26:12

preferred resources for the statin interactions or do

26:15

you just know these off the top of your head at this point? I

26:18

always double-check you know I think I

26:20

always double-check you know there's a couple great

26:22

resources I think University of Washington

26:24

has this like self-study module for HIV

26:27

and also HIV and primary care. It's

26:29

free, it's amazing. They also have one for Hep C.

26:32

UCSF also has one where I think they're

26:35

just revamping the website because it's been off for

26:37

about a year and it's called the Knowledge Link

26:39

and it's great because it's all topics necessarily

26:41

all towards there. Those are my kind of

26:45

go to ones and then I know I'm digressing

26:47

a little bit but I think as I talk about my patients

26:49

is really focused on smoking

26:52

because there's a much higher the prevalence of smoking

26:54

in patients living with HIV. And I describe

26:57

it as, you know, a couple years ago, our

26:59

journal, Clinical Infectious Disease, had a article

27:02

on smoking and smoking conversations

27:05

to have with patients, reviewing their treatments for patients,

27:07

you know, pretty much a primary care

27:10

article in a infectious disease journal.

27:12

And I think it just shows that the prevalence of smoking

27:14

is much, much higher. Yeah.

27:17

The quit line in

27:19

the state of Pennsylvania is great. They give five

27:21

free coaching sessions and they'll send patients

27:24

patches and then either gum or lozenges for

27:26

free. So it's a fantastic

27:28

resource. And I think it's a national resource. I

27:30

think if you call, you actually get a person

27:33

too. So I would recommend people

27:35

just even call it yourself just to see like what

27:37

experience the patient's got. I've done it and

27:39

it is very

27:42

helpful.

27:43

I wanted to ask a little

27:45

bit about,

27:47

or no, I'm sorry, I wanted to note the Liverpool calculator,

27:49

isn't that the one that like all the ID docs, I

27:52

think it's been mentioned on the show before. I think

27:54

they have one for hep C, for HIV, and for

27:57

the COVID medications, I think. Yeah, and thank you for bringing

27:59

that back.

28:00

because that one's also a very helpful source. I've

28:02

used it a lot during COVID, especially just

28:04

a magic check for the Pax Levitt interactions.

28:09

This episode is brought to you by

28:12

Birch Living. And audience, you

28:14

know that my wife and I, we love

28:16

our Birch mattress. We've had it for over two years

28:18

now, and we would not trade that thing in

28:21

because it is great. It's comfortable,

28:23

stylish, and we love it.

28:25

Now, Birch is making mattresses for kids.

28:28

These kids mattresses have a two-side design

28:30

so they're firmer when the kids are younger, softer

28:33

when the kids get older, they have an anti-microbial

28:35

shield, hypoallergenic cover, and

28:38

because kids are gross, they're water and

28:40

stain resistant.

28:42

These mattresses are made right here in America from

28:45

natural and organic materials. Of

28:47

course, there's a 100-night free sleep trial

28:50

and they have a 25-year warranty. So

28:53

what are you waiting for? family, including

28:55

my kids, we love

28:57

our birch mattresses. So birch

28:59

is giving 20% off all mattresses

29:01

and two free eco-rest pillows at birchliving.com

29:05

slash curb. That's 20% off and

29:07

two free eco-rest pillows at birchliving.com

29:11

slash curb. Sleep better

29:13

with birch.

29:18

All right Paul, where to next? Well

29:20

it's Valentine's Day. I mean we should probably why

29:23

she is Valentine's Day. Happy Valentine's

29:25

Day. Thanks to you too, buddy.

29:27

So actually, let's talk about, because I do want to

29:30

make space for this too, about the conversations

29:32

about transmissibility in relation

29:34

to, say, viral load in CD4 counts. Or what's

29:37

the current thinking, the current counseling? Can we, I just

29:39

want to make sure that we talk about the u equals u before we move

29:41

past it into the other screenings. Yeah,

29:43

so I think this was big when this

29:46

came out with CDC. I think there was many

29:48

studies that were already super suggestive

29:50

of this. there is a study which I

29:52

can't remember all. I think it was HPTN052.

29:56

You might quote me on that one. I should know that

29:57

one, but I think overall, I was looking at zero discord.

30:00

couples and what they noticed in serial-descorbent

30:02

couple one living with HIV, one without is that

30:05

the patient, as long as the patient was undetectable,

30:07

actually did not contract, was unable

30:10

to transmit HIV. And there's been several

30:12

iterations of it from different parts. There's the partner

30:14

studies and the partner two studies that looked at more

30:16

diversified patient populations

30:19

and same thing. So when we're looking at

30:22

patients that are MSM or gay, bisexual,

30:25

they were able to extrapolate that

30:27

as well, that U equals U. So really

30:30

thinking about treatment is not just treatment.

30:32

It's also preventive. So that's why I think

30:34

a lot of our Treatment options have

30:37

really focusing on starting medications very early

30:39

on. It's crazy like ten years ago I would

30:41

wait till they're a defining illness just talking about this.

30:43

Yeah, yeah, and I was a when I was a resident I

30:46

think the smart trial came out. So it was like CD4

30:49

come up 500. Yeah, and you

30:51

know really talking about the rapid initiation

30:53

and really bringing down that viral load as

30:55

quick as often And there's a lot of stuff from UCSF

30:58

also looking at bringing down that viral load

31:00

very quickly with same day initiation. You just got to

31:02

remember there's some patients that you may want

31:04

to do that too. There might be others that you want

31:06

to be careful on actually.

31:09

Yeah. And

31:10

I wanted to, you know, this is something I do

31:13

on the show from time to time. So I maybe

31:15

I'll tell me if I'm wrong. I might be wrong. Feel

31:17

free to shoot this down. He's going to be wrong, by the way. We

31:20

should just check the CD4 account. That's still most

31:22

important. and we should just check it like every

31:25

month or so for just the entire time

31:27

the person has HIV. What's the current

31:29

thinking on that? Am I up to date? So,

31:32

you know, we'll check a CD4 count initially

31:34

as a baseline when we're thinking of treatment

31:38

naive, mostly to give us an idea

31:40

of,

31:40

you know, if there's issues with us to think about

31:43

for opportunistic infections prophylaxis.

31:46

You know, the absolute number is what my patients are so

31:49

on and remember, but to me, just

31:51

as important as the CD4 count the percent because

31:53

the absolute number can change. Someone can be

31:56

ill, hospitalized with a pneumonia, come in with a colitis,

31:58

that absolute number can come down.

32:00

the percent tends to be less

32:02

variable. For how often we check it,

32:04

so I usually will check it within

32:07

three to six months, in the initial

32:09

part. As patients who've been undetectable

32:12

for greater than two years, I've sometimes just switched

32:14

to once yearly, actually. It

32:16

also is patient driven. There are some patients that

32:18

are really, that is super important for

32:21

them to know. So I think

32:23

that's

32:24

something that I keep in until my thought as well. It probably

32:26

depends on when they were diagnosed too, right? Yeah, I

32:28

mean we had talked years ago with Michael

32:32

Sagg and he was just like, yeah, viral load is what's

32:34

important now, suppressing that. Once someone's

32:36

viral load's suppressed and their CD4's greater

32:39

than 500 and stable for years, like

32:42

checking it has minimal value at that point

32:44

if they're staying

32:45

on their meds. I would agree with that. I

32:47

think some reporting that some funding comes

32:50

from different states for like our Ryan Wright program

32:52

still are on that. They still want that. I still want

32:54

that. But I think I agree with that. To me,

32:56

the bigger thing is making sure at the viral load. And

32:58

that's what I'm going to be checking more often, especially

33:00

I want to make sure that's dropping within a log, actually.

33:03

And with the introduction in integrase inhibitors, it does.

33:06

Where I get worried is if it's not. And that's

33:08

when you've got to start thinking about, hey, were

33:10

there barriers for adherence? Is

33:12

there some underlying resistance that I might

33:14

see? And that's where I might focus on. But

33:17

one thing I forgot to mention, even as I'm having

33:19

this discussion with this patient, too, is

33:23

taking a really good sexual history. Because

33:25

one of the big things I want to make sure is that

33:28

if their patient partners get offered PrEP

33:31

or discussions about HIV PrEP. And I know these

33:33

guys have done talks on HIV PrEP. I won't

33:35

focus so much on that. And then

33:38

also take a really good sexual history as

33:40

well. Yeah.

33:41

So before I actually, I would like to hear what

33:43

your sexual history sounds like before we get there and

33:45

before we leave this slide. Is there a recommended

33:48

duration of time for someone to be undetectable

33:50

before you can say with confidence, OK, equals you? Is

33:52

there guidance, recommendation for that? Is one lab sufficient?

33:55

How was the timing about that? So

33:59

back what I always.

34:00

remember when I'm talking about family planning, I would like

34:02

to make sure that they're undetectable for at least six months.

34:04

But I think honestly, the data suggests that if

34:06

they're been undetectable with viral loads

34:09

less than being

34:11

detectable, it reduces the chance.

34:13

Perfect. OK. And I know that you wanted to talk

34:15

about your sexual health history. This

34:18

feels like the right time. So I would say

34:20

that the greatest thing I've ever

34:22

had, honestly, was working with

34:24

a young patient population. Because they really

34:26

broke me down in the sense of like terms,

34:29

lingo, like everything. And I still learn so

34:31

much from them. I have a, it's a joy

34:33

taking care of them. I always think

34:35

of, there's actually an insert from like the CDC

34:38

and it's really thinking about like the five P's. Now

34:41

I don't always remember all the P's, but it's still good. So

34:44

I think one is like looking at practice. So

34:46

like, you know, what is their practice? So I usually

34:48

will go in, like, I always start off with like, I have no assumptions,

34:51

just tell me like, you know, what preference

34:53

of partners do you have? trans be female

34:55

by, you

34:57

know, overall how do you practice, top,

34:59

bottom, verse. Usually I preface

35:01

this by, this is important for me to think about for testing.

35:04

So like I usually will preface that from that. Sometimes

35:06

I'll even ask them, you know, have they been tested in that

35:09

modality before overall. I

35:12

think the next thing I kind of get to is number of partners

35:14

within the last three to six months. So again,

35:16

it gives me an idea of how often to do STD screening, making

35:19

sure that that's offered. thinking about

35:22

HIV prep if there's like also partners that

35:24

they're necessarily having that might be interested in

35:26

that as

35:27

well. You know, I think

35:30

also prior history,

35:32

so again, knowing if they had previous histories

35:34

of STDs, mostly to make sure that they get tested

35:37

more frequently, and then also to make sure that

35:39

they're getting tested correctly. A lot of times I see

35:41

the primary care providers, amazing, they'll do a good job

35:43

of screening. They forget the check syphilis. So

35:45

like a lot of times I'll see like the urine and the

35:48

swab, but I won't see the RPR

35:50

actually. So just there's higher rates of syphilis

35:54

as expected. And then one other thing that might be

35:56

a little bit different in my patient population is hep C. So

35:59

there's.

36:00

There's been some

36:01

data looking at sexual

36:03

transmission, mostly in MSM. So

36:06

there's been thoughts that screen hep C might

36:08

want to have a discussion with patients to screen yearly,

36:11

actually. So that might be something else in my practice. And

36:13

making sure they're immune for hep B is also

36:15

a part of my practice. So like looking through all

36:18

these is making sure that if we do have the

36:20

swabs to do recto-infringial testing,

36:22

that should be included as well,

36:24

because we'll catch more cases that way. Yeah. We

36:28

did a STI episode years

36:30

ago and I

36:31

again was embarrassed to not know that. I

36:34

was just like, oh,

36:34

do the urine nucleic acid amplification

36:37

test

36:37

and I'm good to go. And our guest is like, no, you

36:39

miss a ton if you do that. Like you have to ask them

36:41

like, how are you having sex? You know, if and

36:44

then you have to do rectal swabs or pharyngeal

36:46

swabs, as you just said, as well if

36:49

that's happening. So I think that's,

36:51

we can't say that enough so that people remember to

36:54

do that. What

36:55

else, Paul? I wanted

36:57

to ask about, well,

36:59

actually, I guess, let's get into the labs first. So

37:02

we have some of these up here. Hopefully, they're

37:04

reasonably accurate. But I guess, let

37:08

me go back to my original question. I heard

37:11

rumblings about doxycycline for

37:13

STI prep. Can you talk me where are we

37:15

at with that? How should we be thinking about that? Is that something that

37:17

is commonly used? Sure. When I was in

37:19

Philadelphia, there was an arm of the hypergase

37:22

study that looked at doxycycline to

37:24

look at reducing the cases

37:26

of syphilis and chlamydia.

37:29

As the advent of HIV prep, great

37:32

in preventing HIV expectations

37:34

that there's been higher cases of STD, especially

37:36

in certain patient populations where there's just

37:38

much, much higher cases overall. The

37:41

thought process is that it's really thinking

37:45

about post-exposure prophylaxis, because

37:47

what they're looking at is providing doxycycline,

37:49

which is 200 milligrams within. You want to do

37:52

it within 24 hours, but up to 72 hours after

37:54

condomless sexual activity. And

37:56

what they noticed is that it actually decreased syphilis

37:59

case. and chlamydia cases, UCSF

38:02

and their state health department, I thought, had just

38:04

come out with a study, because it was kind of mentioned

38:07

in the International AIDS Conference from last summer,

38:10

actually looking at doxycycline, and they were

38:12

only looking at it for MSM. So it's only really,

38:14

MSM, it's cis

38:17

men or trans females, to think about when we're

38:19

talking about doxy prep, actually, and

38:21

what their, although there's ongoing studies looking

38:24

at it for cis females as well. But

38:27

what they noticed was that reduced STDs, but

38:29

up to 66%. And as

38:32

a former, before ID

38:34

fellowship, I was an epidemiologist, and

38:36

I can tell you, I've never done syphilis contact tracing,

38:38

but I've done other contact tracing. Takes up

38:40

a lot of time and resources to really

38:42

find patient zero. So when you're trying to find

38:45

and track cases of syphilis, how

38:48

much resources are spent, thinking

38:50

about conversations about doxypep might

38:53

be something to actually talk about. And

38:55

this is a daily doxy dose

38:57

to prevent? It's two different ways. So

39:00

most ways I've used it is mostly as

39:02

post-exposure prophylaxis. So 200 milligrams

39:04

within the 72 hours, really

39:06

try to put it 24 hours. There's other studies that are

39:08

coming from Canada and Australia that are

39:11

both looking at both PEP and Doxy

39:13

Prep as well. So there might

39:15

be stuff coming about because next week is our

39:17

big retrovirus and opportunistic

39:19

conference, which is a mouthful. So we just call it CROI.

39:22

So CROI. So there might be some updates. By the time

39:24

this airs, we might have to update the show. You'll let

39:27

us know if you need to update the show notes by the time

39:29

this airs. But the question comes

39:31

on who to think about it. So when I was

39:33

in Philadelphia, I remember the health department meeting

39:35

with us and just talking about

39:37

how much resources they use for syphilis testing.

39:40

And there had been discussions and reflections on should

39:43

we be thinking about doxypeps. So it's a conversation

39:45

that I've had for my patients. I think of any

39:47

patients that had more than one or two STDs actually

39:50

within a year, especially if it

39:52

was syphilis, actually. So it's like one

39:54

of the big things have had discussions with

39:57

the controversy or the part did not know in that

39:59

study. the most recent one was there was more

40:01

resistance to gonorrhea. Like it reduced it,

40:03

I think by 50%. Yeah, we don't want super gonorrhea

40:06

to get any more prevalent than it. But the

40:08

caveat is that we don't really use tetracycline

40:11

for gonorrhea treatment. But

40:13

the question is, well, will it change the biome

40:15

or resistance for other stuff that we use doxycycline

40:18

for, right? So when we think about staph infections

40:20

and stuff like that. So I think there's still a lot of data. So

40:22

like CDC's inputs like,

40:24

hey, it can be used off-label,

40:27

but there's still need a lot of data. Well,

40:30

I wanted to ask, because

40:32

we do want to leave time

40:33

for audience questions. I know we have

40:36

a lot of other stuff to test for. I did want

40:39

to ask about anal cancer screening,

40:41

because that's, I think probably most primary care

40:43

docs are less familiar with that. And

40:45

talking about doing digital rectal exams and

40:48

anal PAPs, are you doing those in the

40:50

off? Like who's doing those? Should primary

40:52

carers be doing those? if their patient's

40:54

not seeing an HIV specialist, really?

40:56

Sure, yeah, I've been doing

40:59

anal pap screening.

41:02

I did a lot of it before coming

41:03

to Penn State Hershey. The

41:06

issue sometimes I worry is that the costs of

41:08

the testing for patients prior, but I

41:11

think a lot of things have swayed in the last couple

41:13

years. Last year at CROI, the anchor study

41:15

kind of gave out some preliminary results looking

41:17

at anal cancer screening. So I'm

41:20

trying to remember what the anchor study stands for, things like

41:22

anal cancer, high-grade

41:25

squamous intraepithelial lesions.

41:28

Oh, that's great. Yeah, it's probably a cardiology

41:30

trial. That's not bad. Yeah, yeah. But

41:33

what they were looking at was they were screening patients over the

41:35

age of 35. They had both men and women, trans-female, trans-males

41:38

as well. And they were looking through and

41:41

seeing if a patient tested

41:43

positive for a high-grade lesion, should

41:45

they just take it out or should they just monitor

41:48

it? And the study actually had closed early. It

41:50

was between 15 different sites overall

41:52

in the U.S. and just because

41:54

there was clear benefit necessarily from it.

41:57

So it's something that I've been doing a lot

41:59

more in my patients. and practice and having that discussion

42:02

overall. And

42:04

I've caught a lot of high grade lesions. And then

42:07

after that, really tying them for the anoscopy

42:09

or colorectal to take a look to make sure if there's any

42:11

suspicious lesions. And then after that, follow

42:13

up with colorectal. And any resources

42:16

for people? I mean, I don't

42:18

think I did not learn how to do that. I know I

42:20

did not learn how to do that in training. So what resources

42:22

are there for people if they have to learn

42:24

how to do anal path? Yeah, so there's what

42:27

we call, there's a wonderful iteration

42:29

and stuff from some of the health departments overall.

42:33

It sounds more difficult than it is. It's

42:36

just a brush, actually, overall. And

42:38

you're trying to get around the z-line and putting pressure

42:40

as you go in, put pressure as you go in, and then

42:42

just spin as you go out. It's

42:45

been, you can Google it. There's many

42:47

different things in PDF. And patients can't

42:49

self-swab for that. That's one where we don't

42:51

recommend necessarily self-swabbing. And then

42:53

sometimes also thinking recto

42:55

exam, digital exam, just making sure you're not missing the

42:57

lesion from the brush. So those are things

43:00

I've had discussions with my patients

43:02

and recognized that overall,

43:04

they may not want to do that at the moment. Or

43:06

I don't save it for the first visit. It might be stuff as

43:08

we develop rapport. OK, great.

43:11

And along those lines for cervical cancer screening,

43:14

I know things are a little bit different for patients living with HIV.

43:17

You don't have to go too, too granular, but

43:19

any big differences between anything

43:22

that you would do differently for someone who is living with HIV

43:24

than someone who is not? Yeah, so I think

43:27

if I remember correctly from the primary

43:29

care guidelines, usually age 65, you

43:31

would necessarily stop for cervical cancer

43:34

screening in patients not living with HIV. In

43:36

persons living with HIV, actually

43:38

it goes on past that. So overall,

43:42

also depends, we try

43:44

to do it within the first time of diagnosis,

43:46

but still go by the guidelines, so nothing

43:48

earlier than necessarily 21. And

43:50

then I always have to look at the flowchart

43:52

overall to make sure that I remember, but

43:55

excellent chart up there that you're

43:57

showing.

43:59

So Paul, I

44:01

think we should leave a

44:03

few minutes for audience questions. We have some time left. But

44:05

what else do you definitely want to get to? I know we've got

44:07

into a lot of the stuff on here already. I think the

44:09

things I want to hit for sure, any differences in vaccines.

44:12

And then I think

44:13

we should probably finish up with the future is the injectable

44:15

stuff, because I feel like that's an important conversation to have. So why don't

44:17

we, any difference

44:19

in terms of vaccine considerations for someone with a diagnosis

44:22

of HIV? Yeah, I think as I think

44:24

about

44:26

necessarily vaccines, making

44:28

sure that they're definitely screened for

44:31

hep A and hep B. So making sure that

44:33

they're hep A and hep B immune.

44:35

Actually, again, for prevention

44:38

as an STD, but also co-infection, there's

44:40

worse liver with co-infection. Strep

44:43

the caucus pneumonia. So really thinking

44:45

about strep pneumo vaccinations actually

44:47

indicated there's higher rates. Which ones? Right.

44:50

I always, yeah, same thing. So usually I start

44:52

off with the PCV 15 and then 23. No.

44:58

I got to look at it again. It's changed so much

45:00

recently. It's what it's a day before. It's usually 23.

45:02

Yeah. Yeah. And then the other things to think about meningococcal

45:05

will vaccinate every five years for

45:08

meningococcal. And then even when I was

45:10

looking at the ACIP guidelines,

45:12

thinking about recombinant zoster

45:14

as well.

45:16

Yeah, I know they're trying to simplify. They tried to simplify

45:18

the pneumococcal guidelines, but I still think

45:21

it's still, because there's been so many

45:23

changes in quick succession and there's two new

45:25

vaccines, the two new PREVNARS, I feel

45:27

it's still confused and people are still confused.

45:30

Patients are like, didn't I already have two pneumonia vaccines?

45:32

So anyway, I'm on your side about, I'm on team JJ

45:35

for this one. I'm genuinely angry

45:37

about the pneumococcal vaccinations, which is not great for my patients.

45:39

Well, you know, I think like there's still some tables that

45:41

I have where I usually sit in my pod in clinic

45:43

and I'm like, yes, I'm still up to date on that one. Yeah,

45:46

all right. Well, let's talk about, I

45:48

was excited, I think the first I heard about

45:50

this

45:50

was last year at probably

45:52

ACP talking about the injectable

45:55

medicine, both for prep and for just like

45:57

once, once every eight weeks injectable.

46:00

and they don't have to take a daily pill. Can

46:02

you talk about this? Is this, are

46:05

there any barriers to this? Any downsides to

46:07

this?

46:08

So I think this has been really exciting. A

46:10

lot of patients had been hearing rumblings

46:12

for quite a while. As I mentioned

46:15

to you, it's very easy for me to come in and go, hey, take your

46:17

medication every day. Easy, but

46:19

I have patients that, it's a constant reminder

46:22

of their diagnosis necessarily. I have patients

46:24

that hide their pills or their transitional

46:27

housing in between, So like not making sure

46:29

that they don't want anyone to know that they necessarily

46:31

have HIV. And then I have other patients

46:33

that have just trouble taking pills. So when

46:35

this came out, it was really awesome to kind

46:37

of really talk about different treatment

46:39

options overall. One of the big

46:41

things is it can't be used with Hep B. So they have

46:43

to be hepatitis B, can't

46:47

have chronic hepatitis B, as we tend to

46:49

use tenofovir a lot for heptie

46:53

infections. But I think it's been really

46:55

revolutionary and really giving some of the

46:57

autonomy back to the patient that they don't

46:59

have to take a daily pill. When they were looking at the studies,

47:02

there's two, actually one that we're looking at it monthly,

47:04

the other looked at higher dosing and providing the

47:06

first shot, then the second shot, and then after that, every

47:08

two months. And patients did well.

47:10

There was not

47:12

as many breakthroughs overall from becoming

47:15

detectable. So I think it's a really effective

47:17

tool in our toolbox. Couple of caveats

47:20

to it is that it has to be done in a medical

47:22

visit. So because it's a gluteal

47:25

injection, actually it has to be

47:27

done. And I always tell it is that commercial is awesome.

47:30

I love the commercials. Commercial doesn't tell you that's

47:32

actually two shots. So like

47:34

actually as you're selling it with

47:37

the patients overall. So like the- Wait,

47:39

two shots on the same day? Yeah, so one

47:41

per

47:43

gluteal cheek. So

47:45

like as I just- I think you started with gluteal and then someone with

47:47

cheek at the end. Like you started out medical and then just

47:49

kind of- Sorry. You know, that's how I talk about it with my

47:51

patients. But I think one of the big things to really

47:53

highlight overall from it is from

47:56

the patients that have had transition,

47:58

they've absolutely loved it. I mean. And I think one

48:00

of the big things that I really

48:02

want to try to make sure is I need to

48:04

have a way to find our patient. And

48:06

I think that's the hard part sometimes is like, you

48:08

know, you have to remember to come

48:11

back to get that second shot.

48:13

You know, we have a little bit of a window or wiggle room,

48:16

but the always concerning part is if you pass

48:18

that window and the levels are starting to come down and

48:20

we're promoting resistance actually. So

48:23

you know, I've been having my patients do it.

48:25

We try to track it as best as we can, but I

48:27

think sometimes it's just that might be a

48:29

barrier to think about as implementing is really

48:31

the patient follow-up and retention.

48:34

And then the other thing I mentioned is that injectable

48:37

repivirin, so I also do a lot of methadone,

48:39

so like injectable repivirin can actually prolong

48:41

QTC. So like one thing to remember

48:43

is that if there's other QTC prolonging agents

48:46

to make sure there's a baseline EKG, and

48:48

cabbatagravir can actually interact with methadone. So

48:51

it can actually lower the dose. So it's something to think about

48:53

when you're discussing if they're getting methadone

48:56

with their site to make sure that they're

48:58

mentoring for any withdrawal symptoms overall.

49:01

And logistically with these, do you do an oral

49:03

run-in period for tolerance? Like are the

49:05

oral medications first and then transition to the injections?

49:08

So what does this look like? I know probably more than I need

49:10

to know specifically. No, no. So it's a great question.

49:12

For some patients, you know, if I

49:15

haven't done an oral lead-in, you don't necessarily

49:17

have to do the oral lead-in. And if you're doing

49:19

a switch, actually, and they're undetectable, they

49:21

tolerate it well. For patients where I've had

49:23

a lot of issue with medication side effects, I'll still

49:26

do an oral lead in just to make sure that

49:28

they're not having any side effects. So I've had patients

49:30

where we cycled through many different

49:31

antiretrovirals overall,

49:34

and that might be the time that I'll talk about it. The

49:36

other thing is just remembering that they can't

49:38

have NNRTI resistance. So if

49:40

they have resistance to ripivirine,

49:42

it's not an option. If there's a lot of integrase-inhabitore

49:45

resistance, it's not an option. But

49:47

I think it's a good discussion to have with

49:49

our patients overall. overall. And then the exciting

49:51

part of Cabotagravir as well is thinking at

49:54

it as an option for prep.

49:56

All right, well, should we take, I think we should

49:58

probably take questions from. the audience. We

50:01

might probably only have time for maybe like one or so,

50:03

but we'll just call on you and

50:05

we'll repeat it for the people in the audience.

50:08

So does anybody have any questions?

50:11

If not, that's okay. We're happy to just

50:13

get some take home points and get you all out of here. So

50:16

the question was, is there a PAP equivalent for

50:19

HPV related cancer screening?

50:21

I believe so.

50:23

I think... Yeah,

50:27

it's okay. If the answer is we're not sure... I

50:29

would say I'm not as sure for that, so I wouldn't feel comfortable mentioning

50:31

it. But that is a great question. Yeah, I know

50:33

people, I have had patients ask me that question.

50:35

They're worried about it. I think some celebrity has,

50:38

you know, head and neck cancer from HPV

50:40

and people are now aware that

50:42

that could be a thing. Any other questions

50:45

from the audience?

50:49

Okay. It feels like a question.

50:51

Just the furious avoidance of eye contact is my favorite thing

50:53

about medical education. All right. But we could, we could end

50:55

on time. Let's get some take home points. Like people,

50:57

we've talked about a

50:58

lot today. I mean, we've done hero's work as

51:01

always. As always. But

51:02

if there was like maybe a couple of things,

51:05

one, two, three things you wanted the audience to remember,

51:07

what would those be? You

51:09

know, I think just making sure that

51:12

we're

51:12

balancing patient expectations

51:14

and what they're looking for in primary

51:16

care, recognizing that barriers that they may have experienced,

51:19

I think that's something to kind of really think about

51:22

as we work with our patient populations. The second

51:24

thing that drives me crazy is the expectation

51:26

that if patients are late, we just reschedule.

51:29

We have no clue how our

51:31

patient's journey to come to our clinic or

51:34

practice that day. And you don't know the competing factors

51:36

that they're necessarily having. So I think one

51:38

of the big things is just being slightly flexible. And

51:41

I think one of the big things is recognizing that when

51:43

a patient has questions that if you don't know the answer,

51:46

just making sure that you can either refer or touch base

51:48

with much smarter colleagues overall

51:51

and not ignoring that. And I bring that up because a lot of

51:53

times, we've always talked about patients mentioning, hey,

51:55

I'm gaining weight, I'm gaining weight, I'm gaining weight, and

51:57

then now there's like a lot data suggesting that hey it's

51:59

true.

52:00

you gained weight on your medication. So I think listening to

52:02

the patients overall. And

52:05

we will be back with our lightning round.

52:09

All right, so before JJ, these

52:11

people know you, but maybe they don't have a

52:13

time to talk to you about like, some

52:15

of the more fun stuff. So maybe

52:18

give them a pick of the week. What are you

52:20

enjoying these days? And that you would recommend

52:22

to them and to the audience at home listening to

52:24

this after the fact. So if I

52:27

kind of want to seem like I'm sophisticated, So

52:29

I probably might start off with an actual book. I

52:31

do love to read. I wish I could say something

52:34

like, memoirs or biographies

52:36

or like stuff, but it's usually sci-fi. So

52:38

I think right now I'm reading The Wandering Earth, which is

52:40

really good. It's about moving this planet

52:42

as our sun is dying. It's very depressing,

52:44

but very good. Sounds right up my alley. Depression

52:47

sci-fi is like my specific niche, so I'll have to check it out.

52:49

And then realistically, probably playing

52:51

video games is my, you know, my stress

52:54

reliever and mass effect. I'm really

52:56

enjoying that. Okay, is

52:58

that available on Switch? Not,

53:00

not the moment. Yeah, I probably won't check

53:02

that out then because, yeah,

53:05

PS5's still hard to come by, maybe, I don't

53:07

know. It's fine.

53:10

This has been another episode of The Curbsiders,

53:12

bringing you a little knowledge food for your brain hole. Yummy?

53:15

I mean, it could have been your chance to shine. Do you want to say, do you want to

53:18

yummy? I'm okay. In front of your colleagues? I mean,

53:20

you can, right here. I'm okay. Great.

53:23

All right, missed opportunity buddy. All right, get your shout outs to thecurbsiders.com

53:25

and while you're there signing for a mailing list to get our weekly show notes in your inbox.

53:28

Plus, twice each month, you'll get our curbsiders digest, recapping

53:31

the latest practice changing articles, guidelines, and news

53:33

in internal medicine. And we're committed

53:35

to high value practice changing knowledge.

53:37

And we'd also like your feedback. Please subscribe,

53:39

rate, and review the show. You can find us

53:41

on YouTube, Spotify, or Apple Podcasts.

53:44

You can also email us at askcurbsiders at

53:46

gmail.com.

53:47

And I wanted to give a special thanks to the great Dr.

53:50

Paul Nelson Williams, America's primary care

53:52

doctor, and to

53:55

Dr. Beth Garbz-Garbatelli for helping

53:57

to write this episode. the curbsiders tech

54:00

is done by the team at Podpaste, Elizabeth Proto, and

54:03

Jen Watto run our social media, and Stuart Brigham composed

54:05

our theme music. And with

54:07

all that, until next time, I've been Dr. Matthew

54:09

Frank Watto. I do want to throw in a quick thanks

54:11

for Dr. Ellen Todaldi, who actually is one of my

54:14

legit heroes, who's at Temple right now, who actually looked

54:16

over the script and gave me some ideas. So I just

54:18

wanted to say thank you to her. And then also just ask for

54:20

another round of applause to the great Dr. Níngez

54:22

before they say hi. I'm Paul Williams. Thanks,

54:25

guys. Thanks guys.

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features